Medical Device Manufacturing - Orthopedic Implants & Surgical Fixation
Strategic Profile
Medartis differentiates itself through proprietary titanium implant technology and precision surgical instruments, targeting specialized orthopedic surgeons and hospitals. The company leverages its established global distribution network across 13+ locations and focuses on innovation in fracture fixation solutions, positioning itself as a niche player in the premium orthopedic device sector.
Cyborg Score Rationale
Medartis demonstrates stable fundamentals with ~CHF 244M annualized revenue run-rate, profitability (EBITDA margin 15.67%), and 949 employees across global operations. However, recent half-year net income turned negative (CHF -1.45M), and market cap of ~CHF 909M limits scale advantages versus larger competitors.
Top Insights
Recent operational profitability decline: H2 2025 net income swung negative to CHF -1.45M from prior-year positive CHF 963K, requiring management attention
Strategic growth through stake-building in complementary technologies: Increased ownership of Keri Medical SA to 47% in March 2023, diversifying product offerings
Market cap efficiency challenge: Despite ~CHF 244M revenue, market cap of CHF 909M trades at 3.7x sales, suggesting valuation pressure or growth concerns
Strong analyst outlook tempered by recent weakness: Target price range CHF 86-105 against current CHF 75.1, indicating analyst confidence but recent 12.93% month-to-date decline
Named Competitors
Orthopedic Implant Systems — Large-cap diversified orthopedic device manufacturer with global scale
Trauma and Extremity Solutions — Major competitor with broad portfolio and strong distribution
Titanium Implant Specialists — Established player in orthopedic and extremity care devices
Craniomaxillofacial Solutions — Hand/wrist and extremity specialty now integrated into Medartis portfolio
Recent Developments
(March 2023) Capital increase of CHF 30 million completed to finance additional 18% stake in Keri Medical SA, increasing ownership to 47%
(April 2022) Senior convertible bond offering of CHF 125-150 million launched to strengthen financial flexibility following Nextremity Solutions acquisition
(2024-2025) Employee base grown to 949 individuals as of November 2025, reflecting organizational expansion to support global operations
Open the full interactive Medartis Holding AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.